Medication info
Ozatran Plus Tablet 100/12.5 mg

Ozatran Plus Tablet 100/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
White to grayish oval coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200710606 · Notified 2007.09.18 · Insurance code 643502000

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum antihypertensive effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood-pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of this drug is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this drug is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial losartan potassium dose of 25 mg cannot be administered using this drug.
Child dose
○ Children (under 18 years of age) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used to manage blood pressure effectively in patients with hypertension who find it difficult to control blood pressure with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum antihypertensive effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood-pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of this drug is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this drug is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial losartan potassium dose of 25 mg cannot be administered using this drug.

Child dose

○ Children (under 18 years of age) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus and newborn, especially during pregnancy; therefore, it should not be used by women who are pregnant or may become pregnant. This medication may pose risks when administered to patients with certain diseases or conditions, such as those with anuria, electrolyte imbalance, severe liver impairment, severe renal impairment, patients on dialysis, or those with specific genetic metabolic disorders, among others. Patients with significantly low blood pressure or existing renal function issues, patients with a history of liver impairment, patients with hyperuricemia or gout, and elderly patients should exercise particular caution when using this medication. The hydrochlorothiazide component can cause electrolyte imbalance, so regular blood tests should be conducted to monitor electrolyte levels, and any symptoms that arise should prompt immediate consultation with a physician. This medication may cause side effects such as skin rash, angioedema, dizziness, cough, abdominal pain, and rarely, serious allergic reactions or liver dysfunction and worsening renal function. Due to potential drug interactions, especially with potassium-sparing diuretics, potassium supplements, certain antihypertensives, nonsteroidal anti-inflammatory drugs, and lithium preparations, patients should consult their physician if taking such medications together. While taking this medication, sudden onset of symptoms indicating low blood pressure or dizziness may occur, so caution is needed when driving or operating machinery. Women who are pregnant or planning to become pregnant must consult their physician before taking this medication and must immediately discontinue use if pregnancy is confirmed, as well as consider stopping breastfeeding if applicable. This medication is not recommended for use in children and adolescents due to a lack of established safety and efficacy. Elderly patients may have a higher risk of experiencing side effects and should be closely monitored when administered this medication. In case of overdose, symptoms such as hypotension, tachycardia, and electrolyte imbalance may occur, so the prescribed dosage should be strictly adhered to; if any unusual symptoms occur, immediate contact with a healthcare facility is necessary. This medication should be kept out of reach of children and stored in its original container to avoid misuse or quality degradation.

Side effects

  • Craniosynostosis
  • Anuria
  • Hypotension
  • Renal failure
  • Death
  • Abdominal pain
  • Edema
  • Palpitations
  • Back pain
  • Dizziness
Show 128 more
  • Cough
  • Sinusitis
  • Upper respiratory infection
  • Rash
  • Angioedema
  • Skin peeling
  • Hemolysis
  • Chest pain
  • Facial edema
  • Fever
  • Orthostatic hypotension
  • Syncope
  • Angina
  • Arrhythmia
  • Cerebrovascular accident
  • Myocardial infarction
  • Second-degree atrioventricular block
  • Loss of appetite
  • Constipation
  • Toothache
  • Xerostomia
  • Dyspepsia
  • Flatulence
  • Gastritis
  • Vomiting
  • Fatigue
  • Anemia
  • Gout
  • Arm pain
  • Arthralgia
  • Arthritis
  • Fibromyalgia
  • Hip pain
  • Joint swelling
  • Knee pain
  • Leg pain
  • Muscle cramps
  • Muscle weakness
  • Musculoskeletal pain
  • Myalgia
  • Shoulder pain
  • Muscle rigidity
  • Anxiety
  • Anxiety disorder
  • Ataxia
  • Confusion
  • Depression
  • Nightmares
  • Paresthesia
  • Insomnia
  • Decreased libido
  • Memory impairment
  • Migraine
  • Nervousness
  • Panic disorder
  • Dysesthesia
  • Peripheral neuropathy
  • Sleep disorder
  • Drowsiness
  • Tremors
  • Dyspnea
  • Epistaxis
  • Nasal congestion
  • Pharyngeal discomfort
  • Respiratory congestion
  • Rhinitis
  • Venous sinus disorder
  • Chest discomfort
  • Alopecia
  • Dermatitis
  • Skin dryness
  • Petechiae
  • Erythema
  • Flushing
  • Photosensitivity reaction
  • Pruritus
  • Sweating
  • Urticaria
  • Blurred vision
  • Ocular pain
  • Burning sensation
  • Conjunctivitis
  • Visual impairment
  • Dysgeusia
  • Tinnitus
  • Erectile dysfunction
  • Nocturia
  • Polyuria
  • Urinary tract infection
  • Weakness
  • Pancreatitis
  • Jaundice
  • Sialadenitis
  • Spasm
  • Gastric irritation
  • Aplastic anemia
  • Agranulocytosis
  • Leukopenia
  • Thrombocytopenia
  • Purpura
  • Necrotizing vasculitis
  • Pneumonia
  • Pulmonary edema
  • Acute respiratory distress syndrome
  • Hyperglycemia
  • Diabetes
  • Muscle cramps
  • Restlessness
  • Renal failure
  • Renal dysfunction
  • Interstitial nephritis
  • Skin mucous membrane syndrome
  • Erythema multiforme
  • Toxic epidermal necrolysis
  • Temporary blurred vision
  • Xanthopsia
  • Acute myopia
  • Acute angle-closure glaucoma
  • Choroidal exudation
  • Vasculitis
  • Anaphylactic reaction
  • Hepatitis
  • Intestinal vascular edema
  • Dry cough
  • Erythema
  • Hyperkalemia
  • Hyponatremia
  • Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a securely closed container that blocks light. It is important to maintain a storage temperature between 1°C and 30°C at room temperature.

Appearance and packaging

Appearance

White to grayish oval coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.